|Awarded On||November 19, 2014|
|Title||Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||University of North Texas Health Science Center at Fort Worth|
|Principal Investigator/Program Director||Andras Lacko|
IMPACT: Approximately 22,000 women in the United States are diagnosed with ovarian cancer (OC) every year of whom over 15,000 will eventually die from this disease making ovarian cancer the most deadly gynecologic malignancy. In addition, despite an initial response to chemotherapy, relapse is a frequent problem in the majority of patients, in addition to developing resistance even to multi-agent chemotherapy. Such developments often necessitate the change to palliative care from a therapeutic approach. Clearly, more effective therapeutic strategies are needed using targeted drug delivery systems to improve the prognosis for OC patients.
TARGETED DRUG DELIVERY: The proposed drug delivery str...